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HLA class I expression was detected in 94% of osteo-
sarcomas (strongly positive in 56%, heterogeneous in 
38%) and negative or weakly positive in 6%, without 
differences between the stages of the disease. HLA-A 
expression was more frequently negative than HLA-B/C. 
Tumour-infiltrating lymphocytes were highly heteroge-
neous and mainly observed in tumour areas with expres-
sion of HLA class I. Density of T cells was significantly 
higher in metastases than in primary tumours and local 
relapses (p = 0.0003). Positive PD-L1 expression was 
found in 13% of primary tumours, 25% of relapses and 
48% of metastases and correlated with a high T-cell infil-
trate (p = 0.002).
Conclusion An increased number of tumour-infiltrating T 
cells and PD-L1 expression in metastases compared with 
primary tumours, suggesting accessibility for T cells, could 
imply that osteosarcoma patients with metastatic disease 
may benefit from T-cell-based immunotherapy.
Keywords Osteosarcoma · HLA class I · Tumour-
infiltrating lymphocytes · PD-L1 · Immunotherapy
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Abstract 
Introduction Immunotherapy may be an excellent choice 
for treating osteosarcoma given its exceptionally high 
genomic instability, potentially generating neoantigens. In 
this study, we aim to investigate the HLA class I expres-
sion, PD-L1 and tumour-infiltrating lymphocytes in pri-
mary osteosarcomas and relapses/metastases, as well as 
their changes during disease progression.
Materials and methods Tumour samples from multiple 
stages of the disease (pretreatment biopsies, surgical resec-
tions of primary osteosarcomas, relapses and metastases) 
were collected and stained for HLA-A (HCA2), HLA-B/C 
(HC10), β2-microglobulin and PD-L1 using immunohis-
tochemistry on whole sections. Density and type of T-cell 
infiltrate were characterised by a triple immunofluorescent 
staining CD3-CD8-FOXP3.
Results Overall, 85 formalin-fixed, paraffin-embedded 
blocks from 25 osteosarcoma patients were included. 
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Introduction
Osteosarcoma is the most common primary high-grade bone 
malignancy, primarily affecting children and adolescents [1]. 
It commonly arises in the metaphyseal plates of the long bones 
of the extremities (i.e. distal femur, proximal tibia), while 
tumours developing in the axial skeleton, pelvis or craniofa-
cial bones tend to occur in older individuals. Osteosarcoma 
patients are treated with curative intent, consisting of surgery 
of the primary tumour and any resectable metastatic lesions, 
in addition to pre- and post-operative chemotherapy [2]. This 
multimodal therapeutic approach greatly improves the dis-
ease-free survival probability, from 10 to 20% with the surgery 
alone, to more than 60%. However, survival for patients with 
relapsed or metastatic disease remains dismal and unchanged 
over the last three decades, as efforts in developing novel 
active agents have been generally disappointing [3, 4]. Osteo-
sarcoma’s genomic complexity is one of the major explana-
tions for the lack of specific targetable mutations or molecular 
pathways. On the other hand, this genomic characteristic and 
the associated high mutational burden may generate specific 
tumour neoantigens, therefore providing potential targets for 
T-cell-based immunotherapies [5–7].
Historically, the first successful example of immunother-
apy was in 1891 when William B. Coley injected a mixture 
of streptococcal bacteria into unresectable bone sarcomas, 
resulting in an immunological reaction and tumour regres-
sion [8, 9]. Recent advances in cancer immunology have 
now revealed the importance of a spontaneous antitumour 
immune reaction to predict response to immunotherapy, 
mostly carried out by cytotoxic CD8-positive T cells [10]. 
Antigen presentation by surface HLA expression on tumour 
cells is an important prerequisite for antitumour immu-
nity since loss or down-regulation of HLA molecules is a 
common mechanism deployed by tumour cells to escape 
immune surveillance [11]. Another immune escape mecha-
nism is the dysregulation of immune checkpoint pathways 
such as PD-1/PD-L1 axis, which has been actively studied 
in epithelial malignancies [12]. So far, data regarding the 
immune microenvironment in osteosarcoma are rather lim-
ited. In order to evaluate the feasibility of T-cell-mediated 
immunotherapies, we assessed HLA class I expression, 
PD-L1 and T-cell infiltration, as well as their changes during 
osteosarcoma progression using immunohistochemistry.
Materials and methods
Patient material
Formalin-fixed, paraffin-embedded materials from osteo-
sarcoma patients with a known stable (n = 7) or progres-
sive disease (n = 18) diagnosed between 1998 and 2011 
were retrieved from the archives of the Pathology Depart-
ment of the Leiden University Medical Center (LUMC). 
Patients characteristics are described in Table 1. Overall, 
85 tissue blocks from 25 patients were collected for this 
study, including pretreatment biopsies (n = 16) and surgi-
cal resections of primary tumours (n = 18), local relapses 
(n = 25) and metastases (n = 26). Material from multiple 
stages of the disease was available for 17 patients, and five 
patients had metastatic disease at diagnosis (Supplementary 
Table 1). Whole sections were used to assess HLA class I 
expression, PD-L1 and T-cell infiltrate in these tumours. 
Diagnoses were confirmed by an experienced bone and 
soft-tissue tumour pathologist (J.V.M.G. Bovée) according 
to the 2013 World Health Organization classification. All 
the specimens were handled in a coded fashion according 
to the Code for Proper Secondary Use of Human Tissue in 
the Netherlands of the Dutch Federation of Medical Scien-
tific Societies.
Immunohistochemistry and scoring
Immunohistochemistry stainings for HLA class I (HCA2, 
HC10 and β2-microglobulin) and PD-L1 were performed 
according to standard laboratory protocols, as described 
previously [13]. Briefly, 4-μm sections were deparaffinised 
with xylene and rehydrated in graded concentrations of eth-
anol. Endogenous peroxidase was blocked in 0.3% H2O2 
solution, and microwave antigen retrieval was performed 
in Citrate pH 6.0 (for HLA class I) or in Tris–EDTA pH 
9.0 (for PD-L1). Subsequently, sections were incubated 
Table 1  Patient characteristics
n 25
Median age (years) 18 (7–70)
Gender
 Female 8 (32%)
 Male 17 (68%)
Pre-operative chemotherapy
 Yes 20 (80%)
 No 5 (20%)
Histological response
 Good 14 (56%)
 Poor 6 (24%)
 Unknown 5 (20%)
Median follow-up (months) 56 (14–117)
Progressive disease
 No 7 (28%)
 Yes 18 (72%)
Metastases at time of initial diagnosis
 No 20 (80%)
 Yes 5 (20%)
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overnight at 4 °C with the different primary antibodies, as 
detailed in Table 2. The next day, the staining was detected 
using poly-HRP and visualised with a DAB+ substrate 
chromogen system. Slides were counterstained with hae-
matoxylin, dehydrated and mounted with CV mount (Leica 
Microsystems). Tonsil normal tissue sections were used as 
positive controls, and primary antibodies were omitted for 
the negative controls. When loss of tissue occurred during 
the staining procedure, specimens were not included in the 
analysis.
Whole sections were scored independently by two 
observers (Y.T. Sundara and J.V.M.G. Bovée or A.H.G. 
Cleven). As semiquantitative scores were used, there was 
a high concordance between observers and in case of dis-
crepancies, the slide was reviewed to reach a consensus. 
The expression of HLA-A (HCA2 staining), HLA-B/C 
(HC10 staining) and β2-microglobulin was assessed semi-
quantitatively as negative/focal weak (tumour cells nega-
tive or focally and weakly positive with positive inter-
nal controls), heterogeneous (both negative and positive 
regions on the same slide) and positive (moderate or strong 
staining in the whole tumour), as used in a previous study 
[13]. Because the light chain β2-microglobulin is an essen-
tial constant component of HLA class I molecules, the final 
HLA class I expression status was determined according 
to the positivity of at least one of the heavy chains stain-
ings (either HCA2, HC10 or both), combined with the 
β2-microglobulin positivity score. Moreover, as many 
tumours were found heterogeneous for the different HLA 
stainings, we also assessed the degree of colocalisation 
between β2-microglobulin and HCA2/HC10. This HLA 
scoring is detailed in Fig. 1e. Positive PD-L1 expression 
was defined as ≥1% of tumour cells or immune cells show-
ing a membranous staining of any intensity, according to 
published data [14]. Additionally, sections with heterogene-
ous expression of HLA class I were scanned using Pano-
ramic MIDI scanner (3DHISTECH Ltd.) to assess colocali-
sation with T-cell infiltration.
Immunofluorescent staining and scoring
For the detection and the characterisation of tumour-infil-
trating T cells, we used a triple immunofluorescent stain-
ing, as previously described [15]. After antigen retrieval 
using Tris–EDTA buffer pH 9.0, whole sections were 
incubated overnight at 4 °C with the combination of pri-
mary antibodies, as detailed in Table 2. The following 
day, isotype-specific secondary antibodies labelled with 
Alexa fluorochromes (Life Technologies) were added dur-
ing 1 h at room temperature and slides were mounted using 
Vectashield mounting medium containing DAPI (Vector 
Laboratories).
Stained sections were observed at 250× magnification 
using a confocal scanning microscope (Zeiss LSM 700), 
and four randomly selected images were processed with 
the ZEN software (version 2.1, Carl Zeiss). The numbers 
of CD3+CD8− (membranous red staining), CD3+CD8+ 
(membranous purple staining) and CD3+CD8−FOXP3+ 
(green nuclear staining) T cells were counted using the cell 
counter plug-in of the program ImageJ version 1.48, and 
the results of the four images were averaged.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware version 23.0 (IBM Corporation, New York, USA), and 
graphs were constructed using GraphPad Prism software 
version 6 (La Jolla, California, USA). Correlations between 
immunohistochemical data and clinicopathological vari-
ables were analysed using Spearman’s rank correlation 
coefficient and Mann–Whitney U tests. For patients with 
material from different stages of the disease, paired t tests 
were used. A binary logistic regression model was used for 
predicting T-cell infiltration based on HLA class I expres-
sion. Correlations between immune markers and patient 
survival were tested using Kaplan–Meier survival analysis. 
Survival curves with immune data from primary tumours 
Table 2  Characteristics of the antibodies and reagents used for immunohistochemistry (IHC) and immunofluorescence (IF)
α anti, A Alexa Fluor labelled, G goat, M mouse
Antigen Antibody supplier Clone/reference Isotype Antibody dilution Secondary reagent Reagent supplier Reagent reference
IHC
 HCA2 Nordic-Mubio MUB2036P Mouse IgG1 1/3200 BrightVision Immunologic DPVO-HRP
 HC10 Nordic-Mubio MUB2037P Mouse IgG2a 1/3200 BrightVision Immunologic DPVO-HRP
 β2 m Dako A0072 Rabbit IgG 1/1600 BrightVision Immunologic DPVO-HRP
 PD-L1 Cell signaling E1L3 N Rabbit IgG 1/400 BrightVision Immunologic DPVO-HRP
IF
 CD3 Dako A0452 Rabbit IgG 1/400 GαR IgG-A546 Invitrogen A11010
 CD8 Novocastra 4B11 Mouse IgG2b 1/200 GαM IgG2b-A647 Invitrogen A21242
 FoxP3 Abcam 236A/E7 Mouse IgG1 1/100 GαM IgG1-A488 Invitrogen A21121
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were generated based on biopsy specimens (16 patients), 
which reflect the natural host immune response and limit 
the impact of any neoadjuvant treatment on tumour micro-
environment, or based on resection specimens when biopsy 
material was not available (six patients). Data from the 
first metastatic lesion were used for assessing overall sur-
vival from the time of diagnosis of metastatic disease (16 
patients). P values below 0.05 were considered statistically 
significant.
Results
HLA‑A is more frequently negative or heterogeneous 
than HLA‑B/C in osteosarcoma
HLA class I expression was determined on whole tumour 
sections by immunohistochemistry using the antibodies 
HCA2 (HLA-A), HC10 (HLA-B/C) and β2-microglobulin. 
Expression of HCA2 and HC10 was mostly membranous 
while expression of β2-microglobulin was both mem-
branous and cytoplasmic. Representative images of the 
different patterns of HLA class I expression (negative/
weak, heterogeneous and positive) are shown in Fig. 1a–c 
and Supplementary Figure 1. A selective lower HLA-A 
expression was more frequently observed than HLA-B/C, 
with 11% (n = 9) of the tumours that did not or weakly 
expressed HLA-A and 70% (n = 57) displayed a hetero-
geneous expression versus 4% (n = 3) and 30% (n = 24), 
respectively, for HLA-B/C (Fig. 1d and Supplementary 
Table 1). Overall, HLA class I expression was strongly pos-
itive in 56% (n = 45), heterogeneous in 38% (n = 30), and 
negative or weakly positive in 6% (n = 5) of 80 evaluated 
tumours, using the scoring described in Fig. 1e. No sig-
nificant difference in HLA class I expression was observed 
between primary tumours, relapses and metastases 
(p = 0.58), neither between pretreatment biopsies and sur-
gical resections (p = 0.48). For the patients with metastases 
Fig. 1  Different HLA class I phenotypes in osteosarcoma. Rep-
resentative staining patterns of HLA-A expression using immuno-
histochemistry (HCA2 antibody): negative/weak expression with 
endothelial cells as positive internal controls (a), heterogeneous 
expression with both negative and positive regions (b) and diffuse 
positive expression (c). Scale bars 50 μm. Negative and heteroge-
neous expression was observed more frequently for HLA-A com-
pared to HLA-B/C (d). The final HLA class I expression status was 
determined according to the positivity of at least one of the heavy 
chains stainings (either HCA2, HC10 or both), dependent to the 
β2-microglobulin positivity score (e)
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at diagnosis, the expression status of HLA class I in the pri-
mary tumour and associated synchronous metastasis was 
found similar while it mainly differed for the patients with 
metachronous metastases (Supplementary Table 2).
HLA class I expression was also evaluated on normal 
bone cells, when present. Osteocytes were mainly nega-
tive for both HLA-A and HLA-B/C, with a more vari-
able expression of β2-microglobulin. A positive but weak 
expression of all markers was often detected on osteoblasts 
(Supplementary Figure 2).
Density of tumour‑infiltrating lymphocytes is higher 
in metastatic lesions
The presence and type of tumour-infiltrating T cells were 
determined by a triple immunofluorescent staining (CD3-
CD8-FOXP3) on whole osteosarcoma sections. Represent-
ative images are presented in Fig. 2a–c and Supplementary 
Figure 3. Density of T cells, defined as CD3 express-
ing cells, was significantly higher in metastatic lesions 
(mean ± SE = 75 ± 13 CD3+ cells) than in primary 
tumours (19 ± 6 CD3+ cells) and local relapses (18 ± 4 
CD3+ cells) (p = 0.0003), as shown in Fig. 2d. In primary 
osteosarcomas, 46% of these tumour-infiltrating T cells 
were CD3+CD8+ T cells, 52% in local relapses and 47% 
in metastases. CD3+CD8− cells (presumably composed of 
CD4+ and γδ T cells) constituted 49 and 47% of the T-cell 
infiltrate in primary tumours and metastases, while this pro-
portion was observed lower (36%) but without statistical 
significance (p = 0.73) in local relapses (Fig. 2e and Sup-
plementary Table 1). The local relapses displayed a higher 
proportion (12%) of CD3+CD8−FOXP3+ T cells, com-
pared to primary tumours (4%; p = 0.15) and metastases 
(6%; p = 0.024). We did not observe CD3+CD8+FOXP3+ 
cells.
Correlation between HLA class I expression 
and tumour‑infiltrating T cells
We attempted to predict T-cell infiltration based on the 
expression of HLA-A, HLA-B/C and β2-microglobulin as 
a single independent variable or combined inter-depend-
ent variables, using a binary logistic regression model. 
We found that the expression status of β2-microglobulin 
together with the expression of HLA-B/C was a significant 
predictor for the total T-cell count (p = 0.04), but not if 
Fig. 2  Characterisation of T-cell density and subtypes in osteo-
sarcoma. Representative images for tumour-infiltrating lympho-
cytes in primary tumour (a) and the associated local relapse (b) and 
metastasis (c). Triple immunofluorescent staining using anti-CD3 
(red), anti-CD8 (blue) and anti-FOXP3 (green) was used to identify 
CD3+CD8−, CD3+CD8+ and CD3+CD8−FOXP3+ T cells. Density 
of T-cell infiltration was higher in metastatic lesions (d), but the pro-
portion of CD3+CD8− and CD3+CD8+ T cells was comparable with 
primary tumours (e). CD3+CD8−FOXP3+ T cells were found more 
frequently in local relapses
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the HLA-A expression status was added to the prediction 
model. Indeed, when we considered tumours with positive 
HLA class I expression including both HLA-A and HLA-
B/C, the mean number of T cells (39 ± 7 CD3+ cells) was 
not significantly higher compared to tumours with het-
erogeneous (33 ± 10 CD3+ cells; p = 0.52) or negative 
HLA class I expression (25 ± 18 CD3+ cells; p = 0.43). 
However, T-cell infiltrate was highly heterogeneous within 
the tumours and we noticed in tumours with heterogene-
ous HLA expression that tumour areas expressing more 
β2-microglobulin and one of the HLA class I molecules 
contained more T cells than tumour areas with low expres-
sion of HLA class I. Consecutive cut sections stained for 
HLA class I and the triple CD3-CD8-FOXP3 combination 
were scanned using a Panoramic MIDI scanner in order 
to illustrate this observation of spatial colocalisation on 
selected areas, as shown in Supplementary Figure 4.
High T‑cell infiltrate associates with PD‑L1 expression
As PD-L1 expression is a possible mechanism for tumours 
to evade immune-mediated destruction, its expression was 
determined by immunohistochemistry on whole tumour 
sections. Membranous PD-L1 expression on ≥1% of 
osteosarcoma cells and/or immune cells (mainly mac-
rophages) was found in 22 of 79 evaluated tumours (27.8%). 
Representative images for PD-L1 staining on a progressive 
disease are shown in Fig. 3a–c. PD-L1 positivity was signif-
icantly higher in metastatic lesions (48%) compared to local 
relapses and primary tumours (25 and 13%, respectively; 
p = 0.004) (Fig. 3d). High density of total CD3+ tumour-
infiltrating T cells and CD3+CD8+ T cells correlated with 
PD-L1 expression (p = 0.002 and p = 0.001, respectively) 
(Fig. 3e, f). We also noticed a frequent spatial colocalisa-
tion between T cells and areas of the tumour with PD-L1 
positivity. Six of the 17 patients with a known progressive 
disease stained positive for PD-L1 in metastases but not in 
primary tumours, and two patients had PD-L1 expression on 
both primary tumour and metastasis. PD-L1-positive metas-
tastic lesions were significantly more infiltrated by T cells 
than PD-L1 negative lesions (mean ± SE = 123 ± 20 vs. 
40 ± 19 CD3+ cells; p = 0.012).
Prognostic significance of immune markers in primary 
tumours and metastases
Although mostly patients with poor outcome were included 
in this study, the time to progression differed between these 
Fig. 3  High PD-L1 expression in metastatic osteosarcoma lesions. 
Representative images for PD-L1 immunostaining in an osteosar-
coma patient. PD-L1 was negative in the primary tumour (a) while a 
membranous expression was detected on isolated cells (mainly mac-
rophages) in the local relapse (b) and was more diffuse and observed 
on both osteosarcoma cells and immune cells in the lung metastasis 
(c). Scale bars 50 μm. PD-L1 expression was observed more fre-
quently in metastatic osteosarcoma lesions, compared to primary 
tumours and local relapses (d). T-cell infiltration was higher in PD-L1 
positive tumours (e, f)
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patients, and there were also patients with non-progressive 
disease. Therefore, the prognostic significance of HLA class 
I expression, PD-L1 and T-cell infiltrate was assessed in the 
evaluable primary tumours (n = 22), as well as in the first 
metastatic lesion (n = 16), using Kaplan–Meier survival 
analysis. Heterogeneous and positive HLA class I expres-
sion in the primary tumour associated with a better dis-
ease-free survival compared to a negative/weak expression 
(p = 0.001 and p = 0.025, respectively; overall comparison 
between the three groups p = 0.002). However, a trend but 
no significant correlation was found for the overall survival 
(p = 0.13) (Fig. 4a, b). To evaluate the significance of infil-
trating T cells, patients were divided in two groups based 
on the median numbers of total CD3+ cells (high and low). 
Patients with high T-cell infiltrate in the primary tumour 
tended to have a better clinical outcome although this was 
not significant. For this group of patients, the median dis-
ease-free survival was 39 versus 19 months for patients 
with low T-cell infiltrate (p = 0.26) and the difference in 
the median overall survival was more pronounced (112 
vs. 40 months; p = 0.15) (Fig. 4d, e). Neither HLA class 
I expression nor density of T-cell infiltrate in the first meta-
static lesion was related to overall survival from the time of 
diagnosis of the metastatic disease (Fig. 4c, f). PD-L1 sta-
tus in either primary tumours or metastases did not correlate 
with patient survival (Supplementary Figure 5).
Discussion
In this study, we investigated HLA class I and PD-L1 
expression, as well as T-cell infiltration in osteosarcoma, 
Fig. 4  Correlation between HLA class I status, total T cells and 
patient survival. Kaplan–Meier survival curves for disease-free sur-
vival and overall survival according to HLA class I status (a, b) and 
density of T-cell infiltration (c, d) of the primary tumour. Overall sur-
vival from the time of diagnosis of metastatic disease according to 
HLA class I status (e) and T-cell infiltration (f) of the first metastatic 
lesion. p value obtained by log-rank test
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to assess the potential application of T-cell-based immu-
notherapies. To characterise the HLA class I expression, 
we used the monoclonal antibodies HCA2 and HC10, 
which recognise HLA-A and HLA-B/C heavy chains, 
respectively, and an antibody specific for the light chain 
β2-microglobulin. Overall, we observed defects in HLA 
class I expression in 44% of the osteosarcomas, mainly 
with a heterogeneous pattern instead of a complete lack 
of HLA class I. Previous studies have reported a loss or 
a down-regulation of HLA class I expression in approxi-
mately 50–62% of osteosarcomas, using a pan-HLA 
class I antibody (EMR8-5) and a cut-off of 50% positive 
tumour cells [16, 17]. In our series, negative or heterogene-
ous expression of HLA-A molecules was found more fre-
quently compared to the other heavy chains HLA-B/C and 
β2-microglobulin. The clinical and therapeutic relevance 
of this finding, if any, has to be further investigated, since 
HLA-A and HLA-B both are antigen presenting molecules, 
and required for T-cell-based immunotherapies.
Another major clinical finding in our series is the high 
density of tumour-infiltrating T cells in metastatic osteo-
sarcoma lesions compared to primary tumours and local 
relapses. CD3+CD8− and CD3+CD8+ T cells were found 
in the same proportion within the tumour microenviron-
ment while the density of CD3+CD8−FOXP3+ T cells 
was higher in local relapses, probably reflecting local 
immune escape mechanisms. Expression of the light chain 
β2-microglobulin together with the HLA-B/C was an 
important predictor of T-cell infiltration. In other cancers, 
particularly with high mutational burden such as mela-
noma, lung and colorectal cancers, a high T-cell infiltrate 
commonly associates with better clinical outcome and may 
predict response to immunotherapy [10, 18, 19]. Although 
not statistically significant, high T-cell infiltrate in primary 
osteosarcomas also tended to have survival benefit for the 
patients included in our study. It has been demonstrated 
that tumour-infiltrating lymphocytes could be easily iso-
lated from adult osteosarcomas and exhibited in vitro a 
high cytotoxic activity, suggesting that therapies based on 
these tumour-infiltrating T cells could be an efficient strat-
egy in osteosarcoma [20]. However, some tumours are 
poorly infiltrated by T cells and the mechanisms associated 
with reduced T-cell trafficking and infiltration are poorly 
understood. A potential mechanism might be the loss of 
the tumour suppressor gene PTEN, frequently reported in 
osteosarcomas [21, 22].
PD-L1 positivity in metastases, while mainly nega-
tive in the associated primary tumours, emphasises the 
dynamics of an adaptive mechanism of immune escape. 
Overall, PD-L1 expression was found in almost half of the 
metastatic osteosarcoma lesions (48%), on both osteosar-
coma cells and immune cells, mainly macrophages. Our 
results are in accordance with other groups who reported 
PD-L1 positivity using another monoclonal antibody only 
in metastatic osteosarcomas, as well as a higher PD-L1 
mRNA expression in metastases, which correlated with 
the T-cell infiltrate [23, 24]. An increased PD-1 expression 
on peripheral CD4+ T cells was also observed in patients 
with metastases, strengthening the idea that PD-L1/PD-1 
axis may play a role during osteosarcoma progression [25]. 
Recently, Koirala et al. reported the discrepancy between 
whole tumour sections and tissue micro-arrays as a result 
of the heterogeneity of PD-L1 expression in osteosarcoma, 
confirming our idea that this immune marker should be 
evaluated on whole sections [26]. Moreover, they identi-
fied PD-L1 positivity as a potential prognostic marker for 
poorer survival, which was not the case in our cohort. How-
ever, it should be noted that we mostly included patients 
with poor outcome, in order to assess the immune changes 
during disease progression. Therefore, our conclusions 
regarding the prognostic value of these different immune 
markers in primary tumours cannot be generalised in all 
osteosarcoma patients.
What is the explanation for the observed low and/or het-
erogeneous expression of HLA class I? In other cancers, 
defects in the antigen presentation pathway were reported 
at different levels (mutations in HLA-A, HLA-B and HLA-
C genes, β2-microglobulin or defects in components of 
antigen-processing machinery) and have been regarded 
as mechanisms to escape from T-cell immune recognition 
[27–29]. Tumour cells that have a loss/down-regulation of 
HLA class I may gain a selective clonal advantage in a pro-
cess called immunoediting, enabling them to escape from 
the CD8+ T-cell-mediated destruction [30].
However, in osteosarcoma, the question can be raised 
regarding the mechanisms involved in the frequent heter-
ogeneous expression of HLA class I. First of all, there is 
scarce data on baseline HLA class I expression in normal 
bone cells. Therefore, it is not clear whether low HLA class 
I expression reflects the normal situation or, in contrast, 
‘down regulation’ as a consequence of escape from T-cell 
immune recognition. An alternative explanation for het-
erogeneity of HLA class I expression could be the conse-
quence of the extreme genomic instability of osteosarcoma. 
But another interesting interpretation would be the induc-
tion of HLA class I expression by interferon-γ secreted 
by T cells. In this study, we observed that in tumours with 
HLA class I negative and positive regions, the T cells spa-
tially colocalised with the HLA class I positive tumour 
areas. Additionally, we observed a strong correlation 
between high numbers of tumour-infiltrating T cells and 
PD-L1 expression. Together, this could imply that, in areas 
of T-cell infiltration, immune activation leads to induction 
of HLA class I and PD-L1 expression. Although it would 
have been interesting to look at the difference in immune 
profile of primary tumour between patients with and 
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without metastasis at diagnosis, we could not answer the 
question due to the low number of samples.
Importantly, and despite the limited number of patients, 
HLA class I expression in primary osteosarcomas cor-
related with a better disease-free survival, which is con-
sistent with previous results [16, 17]. In addition, we 
observed that HLA class I expression in metastases was 
frequently positive, and this was in contrast to Tsukahara 
et al. [17] who reported that HLA class I loss or down-
regulation occurred more commonly in metastatic osteo-
sarcoma lesions (7 out of 8 cases; 88%). Consequently, 
the HLA data from our series can have two therapeutic 
implications. First, the frequent HLA class I expression 
in both primary tumours and metastases highlights the 
potential of (neo)antigen presentation by osteosarcoma 
cells, which can be exploitable in developing personalised 
immunotherapies. Second, identifying the rare patients 
with a negative or weak expression of HLA class I mol-
ecules on primary tumour is of clinical interest, to con-
sider a different therapeutic approach (i.e. strategy based 
on NK cells) [31].
Altogether, the increased number of tumour-infiltrating 
T cells and PD-L1 expression during disease progression, 
associated with a frequent classical HLA class I expression, 
suggest that T-cell-based immunotherapy with adoptive cell 
transfer, peptide vaccines or immune checkpoint block-
ade could be a suitable treatment for metastatic osteosar-
coma patients. Preclinical data demonstrated the benefit of 
PD-L1/PD-1 blockade antibodies, alone or in combination 
with anti-CTLA-4 in a mouse model of metastatic osteo-
sarcoma and the efficacy of pembrolizumab, a monoclonal 
anti-PD-1 antibody, is currently being investigated for bone 
sarcomas in the phase II SARC028 study (NCT02301039) 
[23, 32]. Considering the limited therapeutic options cur-
rently available in advanced diseases, enhancing this pre-
existing antitumour immune response in metastastic lesions 
may offer clinical benefit in osteosarcoma patients.
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